Evotec SE, DE0005664809

Evotec stock: EUR 2.98, up 0.34% premarket

Published on 11/16/2026 at 07:57 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Evotec combines drug research, advanced technology and AI-driven innovation with partners. On Xetra, the stock closed at EUR 2.97 on Friday, November 13, 2026.

Evotec's business and market position

  • Evotec combines technology, drug research and artificial intelligence with partnerships to advance medicines.
  • Just - Evotec Biologics is positioned as a growth catalyst, while the pipeline is intended to generate milestones and licensing revenue.
Evotec SE, DE0005664809, Illustration mit AI erstellt.

Evotec stock gains before Xetra trading

Evotec stock traded at EUR 2.98 on Lang & Schwarz at 07:56 CET on Monday, November 16, 2026, 0.34 percent above the Xetra close of Friday, November 13, 2026.

Evotec develops medicines through technology-led drug research, artificial intelligence and partnerships. The company describes Just - Evotec Biologics as a key growth catalyst and highlights milestone and licensing revenue from its pipeline. Further details are available from Evotec investor relations.

German equities remain the relevant market backdrop for investors following the stock; see current market reports.

More news and analyses on Evotec stock.

Disclaimer...
en | DE0005664809 | EVOTEC SE | boerse | 70519563 | bgmi